Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Taq ruling may not amplify

A U.S. District Court has ruled that F. Hoffmann-La Roche Ltd.'s U.S. patent covering native Thermus Aquaticus (Taq) DNA polymerase is unenforceable and therefore in the public domain. But the pharma company maintains that the decision has little bearing on its PCR franchise, becuase the enzyme is predominantly sold in recombinant forms.

The ruling comes in a suit brought by Roche against

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE